Lifeboat Foundation

The involvement between electron transfer (ET) and catalytic reaction at electrocatalyst surface makes electrochemical process challenging to understand and control. How to experimentally determine ET process occurring at nanoscale is important to understand the overall electrochemical reaction process at active sites.

Recently, a research group led by Prof. LI Can and Prof. FAN Fengtao from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences (CAS) captured the electron transfer imaging in electrocatalysis process.

This study was recently published in the journal Nano Letters.

This paper suggests that ATP release induced by the SARS-CoV-2 virus plays a key role in the genesis of the major symptoms and complications of COVID-19. Infection of specific cells which contain the Angiotensin-Converting Enzyme 2 (ACE2) receptor results in a loss of protection of the Mineralocorticoid Receptor (MR). Local activation by cortisol stimulates the release of ATP initially into the basolateral compartment and then by lysosomal exocytosis from the cell surface. This then acts on adjacent cells. In the nose ATP acts as a nociceptive stimulus which results in anosmia. It is suggested that a similar paracrine mechanism is responsible for the loss of taste. In the lung ATP release from type 2 alveolar cells produces the non-productive cough by acting on purinergic receptors on adjacent neuroepithelial cells and activating, via the vagus, the cough reflex. Infection of endothelial cells results in the exocytosis of WeibelPalade bodies. These contain the Von Willebrand Factor responsible for micro-clotting and angiopoietin-2 which increases vascular permeability and plays a key role in the Acute Respiratory Distress Syndrome. To test this hypothesis this paper reports proof of concept studies in which MR blockade using spironolactone and low dose dexamethasone (SpiDex) was given to PCR-confirmed COVID-19 patients. In 80 patients with moderate to severe respiratory failure 40 were given SpiDex and 40 conventional treatment with high dose dexamethasone (HiDex). There was 1 death in the HiDex group and none in the SpiDex. As judged by clinical, biochemical and radiological parameters there were clear statistically significant benefits of SpiDex in comparison to HiDex. A further 20 outpatients with COVID-19 were given SpiDex. There was no control group and the aim was to demonstrate safety. No adverse effects were noted and no patient became hyperkalaemic. 90% were asymptomatic at 10 days. The very positive results suggest that blockade of the MR can produce major benefit in COVID19 patients. Further larger controlled studies of inpatients and outpatients are required not only for SARS-CoV-2 infection per se but also to determine if this treatment affects the incidence of Long COVID.

Early in the course of the SARS-CoV-2 pandemic it became clear that one of the commonest symptoms was loss of smell and/or taste. Self-reported alterations in smell and taste were detailed in a meta-analysis of 3,563 confirmed cases of COVID-19. They found that the overall prevalence of smell or taste impairment was 47% rising to 67% in patients with more severe disease. In about 20% of patients it was an isolated presenting symptom. Han et al. reviewed the pathophysiology of anosmia in upper respiratory tract infections. Many rhinovirus infections of the nasal olfactory epithelium produce post-viral anosmia which persists for weeks or months until the cell damage is repaired. Post-viral anosmia has been reported with HCoV-229E infection with the olfactory dysfunction lasting more than 6 months. This corona virus does not use ACE2 to get into cells. Conductive or obstructive anosmia is often found with the common cold virus.

The robot navigates using sensors and removes weeds mechanically without the need for chemicals. The LiDAR (light detection and ranging) scanners installed in the weed killer continuously emit laser pulses as the vehicle moves, which are then reflected by objects in the surrounding area. This produces a 3D point cloud of the environment, which helps mobile weed killers to find their way and determine the position of plants or trees. “AMU-Bot is not yet able to classify all plants; however, it can recognize crops such as trees and shrubs in the rows of the tree nursery cultivations,” said the team leader Kevin Bregler.

The weeds in the spaces between the plants or trees are also reliably eliminated. To do this, the manipulator moves into the gaps between the crops. The weeds do not need to be collected separately and are left on the ground to dry out. Thanks to its caterpillar drive, the self-driving weed killer moves along the ground with ease and is extremely stable. Even holes in the ground created when saplings are removed do not pose a problem for AMU-Bot. The AMU-Bot platform is economical, robust, easy to use, and at the same time highly efficient.

The project is funded by the German Federal Office of Agriculture and Food. The AMU-Bot platform relies on the ingenious interaction of three sophisticated modules: caterpillar vehicle, navigation system, and manipulator. Bosch is responsible for the navigation and the sensor system, while KommTek developed the caterpillar drive. The Fraunhofer IPA designed the height-adjustable manipulator, including rotary harrows, and was responsible for overall coordination.

With Gauss Rifles [military squads] could pitch a solar panel, charge their guns’ batteries, and fire nuts and bolts off the ground as ammunition.

“You can hold far more energy in batteries than you can with gunpowder,” Wirth told Futurism. And a battery eliminates the need for “explosive chemical propellants.”

But it’s an entirely new type of armament that could have some potentially dangerous consequences, opening the doors to turn anything from metal rods to nuts and bolts into deadly projectiles. And its creators are already imagining military applications.

Continue reading “A Gun Company Is Now Selling a Handheld Semi-Automatic Railgun” »

Light is an electromagnetic wave: It consists of oscillating electric and magnetic fields propagating through space. Every wave is characterized by its frequency, which refers to the number of oscillations per second, measured in Hertz (Hz). Our eyes can detect frequencies between 400 and 750 trillion Hz (or terahertz, THz), which define the visible spectrum. Light sensors in cell phone cameras can detect frequencies down to 300 THz, while detectors used for internet connections through optical fibers are sensitive to around 200 THz.

At lower frequencies, the energy transported by light isn’t enough to trigger photoreceptors in our eyes and in many other sensors, which is a problem given that there is rich information available at frequencies below 100 THz, the mid-and far–infrared spectrum. For example, a body with surface temperature of 20°C emits infrared light up to 10 THz, which can be “seen” with thermal imaging. Also, chemical and biological substances feature distinct absorption bands in the mid-infrared, meaning that we can identify them remotely and non-destructively by infrared spectroscopy, which has myriads of applications.

ISM001-055 demonstrated highly promising results in multiple preclinical studies including in vitro biological studies, pharmacokinetic and safety studies. The compound significantly improved myofibroblast activation which contributes to the development of fibrosis. ISM001-055’s novel target is potentially relevant to a broad range of fibrotic indications.

“We are very pleased to see Insilico Medicine’s first antifibrotic drug candidate entering into the clinic,” said Feng Ren 0, PhD, CSO of Insilico Medicine. “We believe this is a significant milestone in the history of AI-powered drug discovery because to our knowledge the drug candidate is the first ever AI-discovered novel molecule based on an AI-discovered novel target. We have leveraged our end-to-end AI-powered drug discovery platform, including the usage of generative biology and generative chemistry, to discover novel biological targets and generate novel molecules with drug-like properties. ISM001-055 is the first such compound to enter the clinic, and we expect more to come in the near future [1].”

Previously, Insilico Medicine demonstrated its ability to generate drug-like hit molecules using AI with the publication of the Generative Tensorial Reinforcement Learning (GENTRL) system for a well-known target in record time [2]. It also demonstrated the target’s proof of concept by applying deep learning techniques for the identification of novel biological targets. This novel antifibrotic program combined these target discovery and generative chemistry capabilities. Notably, Insilico Medicine completed the entire discovery process from target discovery to preclinical candidate nomination within 18 months on a budget of $2.6 million.

Subscribe at the link below for new content every Thursday!

Kaleidoscope Presents: We Are Stars.

Continue reading “We Are Stars with Andy Serkis — 360 VR Video” »

The mysterious ways cancer spreads through the body, a process known as metastasis, is what can make it such a difficult enemy to keep at bay. Researchers at Princeton University working in this area have been tugging at a particular thread for more than 15 years, focusing on a single gene central to the ability of most major cancers to metastasize. They’ve now discovered what they describe as a “silver bullet” in the form of a compound that can disable this gene in mice and human tissue, with clinical trials possibly not too far away.

Metastatic cancer is a key focus for researchers and with good reason, as it is actually the primary cause of death from the disease. While surgery or chemotherapy might be effective at eliminating an initial tumor, cells that have broken away can discreetly make their way around the body and give rise to new tumors, months or even years later.

“Metastatic breast cancer causes more than 40,000 deaths every year in the US, and the patients do not respond well to standard treatments, such as chemotherapies, targeted therapies and immunotherapies,” says Minhong Shen, member of the Princeton team behind the new discovery. “Our work identified a series of chemical compounds that could significantly enhance the chemotherapy and immunotherapy response rates in metastatic breast cancer mouse models. These compounds have great therapeutic potential.”

Circa 2019

Cellular enhancement in banana leaves

Banana Leaf Technology started in 2010 when Tenith Adithyaa, then 11 years old, saw farmers in Southern India dump heaps of banana leaves as trash due to the lack of a preservation technology. The spark ignited when the question came to the mind, ‘can these leaves be enhanced biologically?’ By trial and error, he succeeded in preserving the leaves for about a year without using any chemicals. For four years, he perfected his technology of cellular enhancement. He received his first international award for this technology in 2014, at the global invention fair in Texas.

Continue reading “Processed banana leaves, an eco-friendly packaging solution” »